AGIO up +2.48% percent right now. $AGIO High is at 85.45

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
AGIO up +2.48% percent right now. $AGIO High is at 85.45 and the Low 81.48 with current volume of 301,524.

Recent News posted below.

AGIO Agios Pharmaceuticals Inc Recent Headline News

Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.16 (+0.03), PCMI: 8.60 (-0.20), ACHN: 13.18 (+0.33), TGTX: 12.90 (+0.35), AGIO: 83.95 (+2.17), LIOX: 5.35 (-0.19), PLNR: 6.81 (-0.87)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 174.13 (+1.98), SLXP: 97.13 (+3.26), ICPT: 174.77 (-1.58), IBB: 297.41 (+2.21), AGIO: 83.95 (+2.17)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST

AGIO: 83.95 (+2.17)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.40 (+0.02), ANET: 76.61 (-0.18), TKMR: 16.25 (-0.23), ORBC: 6.35 (+0.28), MDRX: 11.13 (-0.15), RMTI: 11.18 (+0.28), CTIC: 2.20 (+0.06), SHLD: 37.86 (-0.86), UBNT: 28.60 (-0.60), RIG: 29.00 (-0.28), KGC: 2.41 (+0.07), APT: 3.02 (-0.09), ANF: 28.94 (+0.25), MITK: 3.37 (+0.22), ZNGA: 2.65 (+0.17), CNET: 2.14 (-0.01), KING: 13.82 (+0.08), NETE: 1.53 (+0.04), SLXP: 97.12 (+3.25), RPRX: 9.08 (-0.14), NADL: 5.02 (-0.10), PGNX: 6.54 (+0.57), AVNR: 13.39 (+0.17), FSLR: 51.48 (-0.48), DVA: 75.00 (+0.28), NDLS: 24.12 (-0.45), ICPT: 174.77 (-1.58), AGIO: 83.95 (+2.17), PLNR: 6.81 (-0.87)

Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST

AGIO: 83.95 (+2.17)

Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 83.95 (+2.17)

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 83.95 (+2.17)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST

BAM: 49.52 (-0.79), ERF: 15.22 (+0.81), LXP: 10.98 (-0.05), PGEM: 13.10 (+0.08), CCOI: 34.25 (+0.98), TTI: 8.65 (+0.07), SJI: 58.22 (+0.24), NXST: 44.94 (+0.42), VSAT: 62.92 (-0.09), MT: 12.13 (-0.12), LXU: 30.90 (-0.59), HUM: 134.50 (+2.04), PGNX: 6.54 (+0.57), MHR: 4.58 (+0.05), CTB: 32.68 (-0.05), IDRA: 2.60 (+0.07), ISIS: 51.08 (+3.85), BPL: 77.33 (-1.29), SSP: 18.41 (-0.15), AGIO: 83.95 (+2.17), EBIX: 16.47 (+0.87)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 93.66 (+0.43), RNA: 12.10 (+0.10), AGIO: 83.95 (+2.17), CELG: 108.19 (+0.18)

Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 83.95 (+2.17)

Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 116.23 (-0.37), LNKD: 228.40 (-0.85), HAL: 53.11 (-0.52), AGIO: 83.95 (+2.17), IMPV: 43.13 (+0.04)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 108.59 (+1.57), CLVS: 61.24 (+1.10), ARWR: 6.39 (+0.18), ACHN: 13.18 (+0.33), MRK: 59.57 (+0.76), RTRX: 10.88 (+0.14), RGLS: 20.54 (-0.37), EPZM: 24.79 (+0.92), AGIO: 83.95 (+2.17), RMTI: 11.18 (+0.28), ARNA: 4.49 (+0.09), KERX: 16.20 (-0.23)

Cramer's Lightning Round - Isis Pharmaceuticals Has The Best Pipeline (10/28/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Oct 29, 5:59AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday October 2 8. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "Isis got slammed, and (the selloff) was overdone. It has the best pipeline...
GS: 192.23 (+0.43), RICE: 28.54 (+0.58), ISIS: 51.08 (+3.85), CYBR: 34.42 (-0.46), GNC: 43.22 (+0.17), HAL: 53.12 (-0.51), AGIO: 83.95 (+2.17), FTNT: 27.15 (+0.03)

'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 47.18 (-0.20), RICE: 28.54 (+0.58), GS: 192.23 (+0.43), FEYE: 32.39 (unch), ISIS: 51.08 (+3.85), CYBR: 34.42 (-0.46), GNC: 43.22 (+0.17), HAL: 53.12 (-0.51), EOG: 98.52 (+0.02), AGIO: 83.95 (+2.17), FTNT: 27.15 (+0.03)

Jim Cramer's 'Mad Money' Recap: Winners in the Expectations Game
at The Street - Tue Oct 28, 7:26PM CDT
It's expectations, not the earnings, that determine the direction of a company's stock price, and several companies proved that today, Cramer says.
KSS: 56.30 (-0.27), FEYE: 32.39 (unch), CYBR: 34.42 (-0.46), FB: 74.37 (-0.63), GNC: 43.22 (+0.17), HAL: 53.12 (-0.51), AGCO: 45.14 (-0.10), BWLD: 161.49 (+2.26), MAS: 23.25 (+0.07), YHOO: 48.74 (-0.67), WHR: 175.46 (+1.67), VSI: 47.18 (-0.20), SAVE: 79.16 (+0.11), RICE: 28.54 (+0.58), GS: 192.23 (+0.43), PH: 127.65 (-0.78), ISIS: 51.08 (+3.85), CMI: 146.10 (-0.40), EOG: 98.52 (+0.02), AGIO: 83.95 (+2.17), TWTR: 39.15 (-0.44), FTNT: 27.15 (+0.03), BABA: 115.44 (-3.71)

Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 21.79 (+1.50), AGIO: 83.95 (+2.17), CELG: 108.19 (+0.18)

Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for  MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 52.84 (-0.66), NVAX: 5.37 (+0.16), AGIO: 83.95 (+2.17), SNY: 46.67 (+0.48), MNKD: 6.11 (+0.23), CELG: 108.19 (+0.18)

Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that it will host a conference call and live webcast on Friday, November 7, 2014, at 8:00 a.m. EST to report its third quarter 2014 financial results and discuss recent business activities.
AGIO: 83.95 (+2.17)

Fab Four - Got To Get You Into My Life
Leonard Yaffe - at Seeking Alpha - Fri Oct 24, 12:24PM CDT

GILD: 108.59 (+1.57), MRK: 59.57 (+0.76), AGIO: 83.95 (+2.17), REGN: 397.80 (+11.83)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Actinium Pharma Unveils Plans at Key Investor Conference

Updated Category News Views 2

Actinium Pharmaceuticals Steps into the Spotlight Alright, folks, here we have Actinium Pharmaceuticals, Inc. gearing up to make some noise at the H.C. Wainwright 28th Annual Global Investment Conference. This isn't just any roadshow—it's a chance to showcase the kind of pioneering work they're doing in targeted radiotherapies. With Sandesh Seth, the Chairman, taking...

Continue Reading
Dr. Rashedi Reveals Laughing Gas Safety for Kids

Updated Category News Views 0

Why Laughing Gas is a Game-Changer in Pediatric Dentistry You ever seen a kid freeze up like a deer in headlights at the dentist's office? I'm telling you, it's not just the sweet tooth nightmare but often the fear of that cold, intimidating chair. But let's talk about a game-changer: laughing gas or, known in the trade as nitrous oxide. Keeping Anxiety at Bay: The Role...

Continue Reading
Signant and Lothar Forge Future in Clinical Trials

Updated Category News Views 1

Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...

Continue Reading
2026 AI Talent Study Reveals Growth and Gaps

Updated Category News Views 2

Pushing Forward Yet Stumbling on the Details We've got a fresh scoop from the AI Leaders Council: They just rolled out their 2026 Corporate AI Talent Study. What's the big fuss? Well, they're tracking how companies are cozying up to artificial intelligence. Let's just say it's a mixed bag this time around. While almost everyone jumped on the AI bandwagon, only a scant 3%...

Continue Reading
Virterion Surges Ahead in VPS Racing With Reliable Hosting

Updated Category News Views 1

Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...

Continue Reading
Patented Foodservice Firm's $1.6M Sale: High ROI Potential

Updated Category News Views 0

Cooking Up High Margins and Rapid Growth You don’t stumble on opportunities like this every day. A foodservice company out there is posting some mouth-watering numbers, and it’s shaking up the M&A scene. This one’s got patents holding up its brand like a culinary force field, and it’s now on the auction block for a cool $1.6 million. And the numbers? Well, they...

Continue Reading
XCOTTON Shines at IFA 2026: The New Horizon of Commerce

Updated Category News Views 1

Shifting Gears at the Checkout Counter Let's face it, we've all been there: you click, you pay, and then you wait. But what happens next is where brands often drop the ball. Sure, e-commerce has been all about getting us to trust the 'buy' button. That's where folks like XCOTTON are stepping up to the plate, giving us something else to consider. They were loud and clear...

Continue Reading
Dreame Unveils Vast AI Product Range at IFA 2026

Updated Category News Views 0

Overnight Sensation or Future Staple? I wonder if Dreame's top brass woke up sweating or smiling after their big reveal at IFA 2026. A buffet of over 100 products across 16 categories is no small feat, especially when you're banking on technologies developed over nine years. But let's cut through the noise—does this showcase promise innovation or just smoke and mirrors?...

Continue Reading
Inturai Ventures Closes Final Tranche with a Twist

Updated Category News Views 4

Wrapping Up a Wild Ride in the Investment Arena Markets are a fickle friend, and today we've got Inturai Ventures calling it a day on their latest cash grab. They've locked the final tranche of their private placement, pulling in an aggregate $963,713.70. Feels like they're counting pennies in this venture, but every cent counts when your aim is to shake up industries...

Continue Reading
AVEX Faces Lawsuit Over IPO Missteps

Updated Category News Views 3

Legal Storm Brewing with AEVEX's IPO Disclosures Whatever happened to straightforward honesty in business? AEVEX Corp. (NYSE: AVEX) might have forgotten that chapter judging by fresh allegations in their midst. Investors who bought AVEX Class A common stock between April 17 and June 4, 2026, have been hit with a curveball: a looming class action lawsuit for securities...

Continue Reading
ing Brands Faces Legal Probe; Fiduciary Duties Questioned"> Continue Reading